Search

Your search keyword '"Livingstone, Julie"' showing total 255 results

Search Constraints

Start Over You searched for: Author "Livingstone, Julie" Remove constraint Author: "Livingstone, Julie"
255 results on '"Livingstone, Julie"'

Search Results

1. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma

2. A polygenic two-hit hypothesis for prostate cancer

3. The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers

4. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression

5. Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis

6. Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease

7. Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry.

8. Loss of CDCP1 triggers FAK activation in detached prostate cancer cells.

9. The telomere length landscape of prostate cancer

10. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse

11. Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression.

12. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer

13. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.

14. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

15. Genome-wide germline correlates of the epigenetic landscape of prostate cancer

16. Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer

17. The Proteogenomic Landscape of Curable Prostate Cancer

18. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations

19. Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities

22. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.

23. Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease

24. Molecular landmarks of tumor hypoxia across cancer types

25. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma

26. Abstract 4305: Germline structural variants shape prostate cancer clinical and molecular evolution

27. Data from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

28. Supplemental Figure 2 In vitro role of FIP1C in regulating cell proliferation in ErbB2/neuNDL primary cells from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

29. Supplemental Figure 3 Characterization of FIP1C/ErbB2/neuNDL cell lines in regulating tumor growth using athymic NCr mice from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

30. Supplemental Materials and Methods from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

31. Supplemental Figure Legends from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

32. Supplemental Figure 1 Schematics of the tetracycline inducible-FIP1C-MTB and inducible knock-out FIP1C mouse models from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

33. Supplemental Figure 5 FIP1C is not distribute at adjacent junctional complexes. Clinical relevance of FIP1C in Her2-positive breast cancer patients from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

34. Supplemental Figure 4 FIP1C is a negative modulator of Akt and MAPK activation in an ErbB2-driven model from Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression

35. A polygenic two-hit hypothesis for prostate cancer

36. Germline determinants of the prostate tumor genome

37. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

38. Combined burden and functional impact tests for cancer driver discovery using DriverPower

39. Integrative pathway enrichment analysis of multivariate omics data

40. Pathway and network analysis of more than 2500 whole cancer genomes

41. Divergent mutational processes distinguish hypoxic and normoxic tumours

42. Genomic footprints of activated telomere maintenance mechanisms in cancer

43. Genomic hallmarks of localized, non-indolent prostate cancer

45. Tumor cell total mRNA expression shapes the molecular and clinical phenotype of cancer

46. The Telomere Length Landscape of Localized Prostate Cancer

47. Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis.

48. Abstract IA-018: Molecular landmarks of tumor hypoxia across cancer types

49. Abstract PO052: Uncovering the evolution of Glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers

Catalog

Books, media, physical & digital resources